Diabetic Nephropathy

糖尿病肾病

• 批准号: 6682466
• 负责人: MICHAEL S MAUER
• 金额: $ 14.91万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6682466
• 关键词: clinical research; computer data analysis; cyclosporines; diabetes mellitus genetics; diabetic nephropathy; epidemiology; human subject; human therapy evaluation; insulin dependent diabetes mellitus; kidney transplantation; longitudinal human study; messenger RNA; outcomes research; pancreas transplantation; patient oriented research; renal failure; renal glomerulus; statistics /biometry; transplant rejection

These continuation studies focus on large pancreas (PTx) and kidney (KTx) transplant populations of type 1 diabetic (D) patients (pts) in order to better understand diabetic nephropathy (DN), the leading cause of renal failure. Objectives are: (a) to determine whether PTx can more readily arrest or reverse the early vs. the more established lesions of DN; (b) to continue studies of renal structural-functional relationships in DN, with emphasis on the multifaceted pathologic DN lesions, including glomerular, vascular, interstitial lesions and glomerular-tubular connections; (c) to continue studies of DN natural history and the role of renal biopsy in predicting outcome; (d) to quantitate and understand the basis of atubular glomeruli (AG) in DN; (e) to elucidate glomerular (glom) epithelial cell abnormalities in DN; (f) to study the glom extracellular matrix abnormalities of DN; (g) to study the recurrence of DN in the KTx; (h) to study the molecular/genetic basis of DN and develop cellular markers of DN risk; (i) to determine the long-term (10-15 yr) structural consequences of cyclosporine (CSA) on the 'native kidneys of PTx recipients; and (j) to determine the shorter-term (5 yr) consequences of Prograf on the native kidneys of PTx recipients and compare these with those seen after 5 years of CSA treatment. Together, these studies will help to elucidate the pathogenesis and natural history of DN, unravel some of the molecular and genetic aspects of this disease, describe the dynamics of DN reversal in PTx pts, and recurrence in KTx pts and expand our knowledge of the nephrotoxic effects of calcinosis inhibitors.

这些持续研究重点关注 1 型糖尿病 (D) 患者 (pts) 的大胰腺 (PTx) 和肾脏 (KTx) 移植人群，以便更好地了解糖尿病肾病 (DN)（肾衰竭的主要原因）。目标是： (a) 确定 PTx 是否可以更容易地阻止或逆转 DN 的早期病变与较确定的病变； (b) 继续研究 DN 的肾脏结构与功能关系，重点关注 DN 的多方面病理性病变，包括肾小球、血管、间质病变和 肾小球-肾小管连接； (c) 继续研究 DN 自然史及其作用 肾活检预测结果； (d) 量化和了解管状的基础 DN 中的肾小球 (AG)； (e) 阐明 DN 中的肾小球 (glom) 上皮细胞异常； （六） 研究DN的肾小球细胞外基质异常； (g) 研究 DN 的复发情况 KTx； (h) 研究 DN 的分子/遗传基础并开发 DN 风险的细胞标记； (i) 确定环孢菌素 (CSA) 对人体的长期（10-15 年）结构影响 'PTx 接受者的原生肾脏； (j) 确定短期（5 年）后果 Prograf 对 PTx 接受者的原生肾脏进行观察，并将其与 CSA 治疗 5 年后观察到的结果进行比较。总之，这些研究将有助于阐明 DN 的发病机制和自然史，阐明该疾病的一些分子和遗传方面，描述 PTx 患者中 DN 逆转的动态以及 KTx 患者中的复发，并扩展我们对肾毒性的认识。钙沉着抑制剂的作用。